Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response
Fatima Karzai(National Institutes of Health), William L. Dahut(National Cancer Institute), Barış Türkbey(National Institutes of Health), Monique N. Williams(Center for Cancer Research), Nicholas T. Terrigino(Center for Cancer Research), John R. Bright(National Cancer Institute), Peter A. Pinto(National Institutes of Health), Adam G. Sowalsky(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Guinevere Chun(Center for Cancer Research), Huihui Ye(Cedars-Sinai Medical Center), Joanna H. Shih(University of Minnesota), Rosina T. Lis(Dana-Farber Cancer Institute), Stephanie A. Harmon(National Institutes of Health), James L. Gulley(National Cancer Institute), David James VanderWeele(Northwestern University), Peter L. Choyke(National Cancer Institute), Stephanie M. Walker(National Institutes of Health), Anna Couvillon(National Institutes of Health), Maria J. Merino, Nicole V. Carrabba(Center for Cancer Research), Scott Wilkinson(Center for Cancer Research)
Cited by 0
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456